General Information
Dasatinib anhydrous is a kinase inhibitor indicated for the treatment of ‘ newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase ‘ adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib ‘ adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
About the API
Systematic name
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
Trade name(s)
Sprycel
Molecular Formula
C22H26ClN7O2S
Molecular Weight
488.00554
Physical properties
white powder
Therapeutic category
Antineoplastic and Immunomodulating Agents
Available formulations
Oral Solid
Regulations
CADIFA
EU DMF
CADIFA
EU DMF